May 9, 2017
Sumitomo Chemical is pleased to announce that a novel long lasting larvicide product – SumiLarv® 2MR, which has been specifically designed for container breeding mosquitoes – has received WHOPES recommendation.
The MR or ‘matrix release’ formulation has delivered impressive performance in extensive lab and field trials conducted in Brazil and South East Asia, offering up to 6 months’ efficacy. The longer residual activity of SumiLarv 2MR offers the prospect of significant cost savings over time compared to traditional larvicide products, which deliver shorter residual efficacy and require retreatment, introducing additional operational costs.
Moreover, and in line with good resistance management strategy, SumiLarv 2MR benefits from a new mode of action for this container breeding larvicide sector as it is based on the insect growth regulator pyriproxyfen. SumiLarv 2MR therefore offers a new tool in the control of mosquito larvae, many of which exhibit resistance to current larvicide products. In addition the product is easy to use – formulated as a small resin disc.
The elimination of the vectors of Dengue, Zika and Chikungunya Aedes aegypti and Aedes albopictus, which are container and water pot breeding mosquitoes, is seen by the World Health Organisation (WHO) as a key element in the control of these diseases. Crucially pyriproxyfen is already approved for use in potable water by the WHO.
Sumitomo Chemical is working with a number of partners and stakeholders globally and anticipates SumiLarv 2MR will come to market by mid 2018.
“Sumitomo Chemical is proud to be at the forefront in the development of innovative vector control products such as SumiLarv 2MR. We are convinced that SumiLarv 2MR will have significant impact on reducing transmission of mosquito borne diseases such as dengue, especially in urban environments, and in doing so will improve the quality of people’s lives,” said Ray Nishimoto, Managing Executive Officer, Health and Crop Sciences Sector, Sumitomo Chemical.
Full details of the WHOPES recommendation will appear on the WHO website shortly.
For more information or to request product samples, contact: email@example.com.
® Sumilarv is registered trademark of Sumitomo Chemical Company Ltd.